Everest Organics manufactures active pharmaceutical ingredients and chemical intermediates, primarily focusing on generic drugs for gastrointestinal and anti-inflammatory treatments for global pharmaceutical companies.
The company operates in a highly commoditized generic API market with no evidence of durable pricing power, as reflected by razor-thin net margins of 2.2% and volatile profitability. While they possess USFDA-approved facilities, this is a minimum requirement for market entry rather than a competitive advantage that protects returns on capital.
Management has prioritized capacity expansion and R&D capitalization despite low returns on equity. Recent actions include a preferential share issuance to fund a new production block, yet historical ROCE remains mediocre at 14.5% and interest coverage is uncomfortably low at 2.1x.
The investment collapsed after the Pollution Control Board issued a permanent closure order due to the company's persistent habit of exceeding sanctioned production limits. This regulatory crackdown coincided with a forced restatement of earnings as auditors finally refused to sign off on aggressive revenue recognition and capitalized R&D. With razor-thin margins already squeezed by commoditization, the company could no longer service its debt, leading to a liquidity crisis that wiped out equity holders while management remained opaque and uncommunicative.
RichFakir rates Everest Organics Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Everest Organics Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Everest Organics Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Everest Organics Ltd's fair value is about ₹47 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →